Acytronix GmbH

Advancing exosome applications with fast, precise separation

Exosomes are cell-secreted vesicles with bio-regenerative properties. MSC-derived exosomes are emerging as a new class of cosmeceuticals for their ability to reduce inflammation, boost collagen, and promote cell repair. Isolating pure exosomes remains a challenge, but ETH spin-off Acytronix has developed an innovative portable microstructured electrochemical device (PMED) to address this. Using antibody recognition and electric release, PMED selectively captures active exosomes, showing promising wound-healing effects in early trials. Now launching PMED for research use, Acytronix also offers collaborative projects. With a team of ETH scientists, e-marketing, and commercialization experts, Acytronix is well-positioned to redefine exosome separation.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (10'000) 2024

Website